Incidental Intense Fibroblast Activation Protein Inhibitor (FAPI) Uptake in Bilateral Gluteal Myositis Ossificans: A Case Report DOI Open Access

Rakan Al-Rashdan,

Saad Ruzzeh,

Nabeela Al-Hajaj

и другие.

Cureus, Год журнала: 2024, Номер unknown

Опубликована: Май 2, 2024

Positron emission tomography/computed tomography (PET/CT) using 18F-fluorodeoxyglucose ([18F]-FDG) is a widely adopted imaging modality for detecting hypermetabolic lesions. However, emerging positron-emitting tracers, such as radiopharmaceuticals featuring fibroblast activation protein (FAP) inhibitors (FAPI) labeled with [18F] or [68Ga], have opened new avenues in nuclear medicine. This case report focuses on the unique behavior of [68Ga]-FAPI bilateral gluteal myositis ossificans, an infrequent condition characterized by soft tissue ossification. A 45-year-old woman gastric adenocarcinoma underwent subtotal gastrectomy and received neoadjuvant adjuvant chemotherapy; PET revealed metastatic processes unexpected avid intramuscular ossifications pelvic thigh muscles. Even though there was no history trauma, patient diagnosed marked non-cancerous ectopic ossifications. Diagnosis relies history, radiology, and/or histology. FAPI imaging, increasingly used inflammatory infectious diseases, can exhibit uptake benign conditions, including those involving bones joints. first to document incidental ossificans. The robust activity ossificans highlights importance considering context calcifications intense uptake.

Язык: Английский

Radiotherapy and theranostics: a Lancet Oncology Commission DOI
May Abdel‐Wahab, Francesco Giammarile, M. Carrara

и другие.

The Lancet Oncology, Год журнала: 2024, Номер 25(11), С. e545 - e580

Опубликована: Сен. 30, 2024

Язык: Английский

Процитировано

38

First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls DOI Creative Commons
Akram Al‐Ibraheem, Ahmed Saad Abdlkadir,

Ula Al-Rasheed

и другие.

Diagnostics, Год журнала: 2025, Номер 15(2), С. 218 - 218

Опубликована: Янв. 19, 2025

Background/Objectives: Over the past four years, 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with 68Ga-FAPI PET/CT, and evaluate influence of PET/CT staging results on changes therapeutic intent compared gold standard molecular imaging modalities. Methods: A total 48 patients biopsy-confirmed solid tumors underwent 77 examinations for assessment, encompassing neoplasms originating from gastrointestinal tract, head neck, hepatobiliary system, pancreas, breast, lung. Results: Notably, pancreaticobiliary exhibited highest uptake, mean maximum standardized values (SUVmax) tumor-to-background ratios (TBR) surpassing 10. comparative sub-analysis PET 20 treatment-naïve revealed significant correlation between tumor grade (Spearman’s rho 0.83; p = 0.00001). Importantly, influenced treatment decisions 35.5% cases, primarily resulting an escalation management plans. 220 challenges were identified 88.3% scans, predominantly within musculoskeletal attributed degenerative (99 observations). Conclusions: comprehensive analysis highlights potential significance oncological strategy, while also emphasizing necessity meticulous interpretation mitigate challenges.

Язык: Английский

Процитировано

2

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer DOI Open Access
Akram Al‐Ibraheem, Ahmed Saad Abdlkadir,

Deya’ Aldeen Sweedat

и другие.

Cancers, Год журнала: 2024, Номер 16(11), С. 1974 - 1974

Опубликована: Май 23, 2024

The objective of this retrospective study is to assess the effectiveness and safety two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total 148 cycles PSMA radioligand therapy were given 53 at a specialized care center Amman, Jordan. This treatment was offered following exhaustion all prior modalities. Approximately half cases (n = 26) demonstrated an initial partial response therapy. Moreover, roughly one-fourth 13) exhibited sustained satisfactory biochemical response, which qualified them receive six maintain continued follow-up for additional cycles. reflected by adequate (PSA) decline concomitant evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. minority (n= 18; 34%) experienced side effects. Generally, these low-grade self-limiting toxicities. endorses previous research evidence about therapy's efficacy. It also provides first clinical insight from Arab ethnicity. should facilitate promote further evidence, both regionally internationally.

Язык: Английский

Процитировано

7

Radiopharmaceuticals in nasopharyngeal Cancer DOI
Xiao‐Quan Xu, Xuemei Tang,

Wan-yin Wu

и другие.

Bioorganic Chemistry, Год журнала: 2025, Номер 157, С. 108281 - 108281

Опубликована: Фев. 14, 2025

Язык: Английский

Процитировано

1

177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening? DOI Creative Commons

Andreas Poschenrieder,

Jasminka Taleska,

Leonhard Schaetz

и другие.

Journal of Nuclear Medicine, Год журнала: 2024, Номер 65(9), С. 1340 - 1342

Опубликована: Авг. 8, 2024

Radiopharmaceutical therapy (RPT) is established as an innovative, effective, and well-tolerated treatment platform approved for well-differentiated neuroendocrine tumors advanced prostate cancer (PC) being investigated in many other cancers such breast, lung, thyroid ([1][1]–[3

Язык: Английский

Процитировано

4

Reshaping [99mTc]Tc-DT11 to DT14D Tagged with Trivalent Radiometals for NTS1R-Positive Cancer Theranostics DOI Creative Commons
Panagiotis Kanellopoulos, Berthold A. Nock,

Eric P. Krenning

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 310 - 310

Опубликована: Фев. 28, 2025

Background/Objectives: Radiotheranostics of neurotensin subtype 1 receptor (NTS1R)-expressing tumors, like pancreatic, gastrointestinal, or prostate cancer, has attracted considerable attention in recent years. Still, the fast degradation (NT)-based radioligands, by angiotensin-converting enzyme (ACE), neprilysin (NEP), and other proteases, considerably compromised their efficacy. The recently introduced [99mTc]Tc-DT11 (DT11, N4-Lys(MPBA-PEG4)-Arg-Arg-Pro-Tyr-Ile-Leu-OH; N4, 6-(carboxy)-1,4,8,11-tetraazaundecane) displayed promising uptake NTS1R-positive tumors mice enhanced resistance to both ACE NEP virtue lateral MPBA-PEG4 (MPBA, 4-(4-methylphenyl)butyric acid; PEG4, 14-amino-3,6,9,12-tetraoxatetradecan-1-oic acid) chain attached ε-NH2 Lys7. We were next interested investigating whether these qualities could be retained DT14D, likewise modified at Lys7 but carrying universal chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic via a (βAla)3 spacer α-NH2 This switch enables labeling DT14D with wide range trivalent radiometals suitable for true theranostic applications, not restricted diagnostic imaging lesions only single-photon emission computed tomography (SPECT). Methods: was labeled Ga-67 (a surrogate positron radionuclide Ga-68), In-111 (for SPECT), Lu-177 (applied radiotherapy). resulting radioligands tested NTS1R-expressing pancreatic cancer AsPC-1 cells models. Results: [67Ga]Ga/[111In]In/[177Lu]Lu-DT14D high affinity human NTS1R internalization cells. They remained >70% intact 5 min after entering mice’s circulation, displaying NTS1R-specific xenografts. Conclusions: Suitably side-chain NT analogs show metabolic stability hence better prospects radiotheranostic application cancer.

Язык: Английский

Процитировано

0

Current Status of Theranostics in West Asia: A Country-based Surveillance Study DOI
Akram Al‐Ibraheem, Ahmed Saad Abdlkadir,

Batool Albalooshi

и другие.

Nuclear Medicine and Molecular Imaging, Год журнала: 2025, Номер unknown

Опубликована: Март 20, 2025

Язык: Английский

Процитировано

0

Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative DOI
Akram Al‐Ibraheem, Andrew M. Scott, Ahmed Saad Abdlkadir

и другие.

Journal of Nuclear Medicine, Год журнала: 2025, Номер unknown, С. jnumed.124.269215 - jnumed.124.269215

Опубликована: Март 27, 2025

Since its inception in 2012, the Nuclear Medicine Global Initiative (NMGI) of Society and Molecular Imaging has played an important role addressing significant challenges field nuclear medicine molecular imaging. The first 3 projects were dedicated to standardizing pediatric practices, global radionuclide access availability, assessing educational training initiatives on theranostics across globe. These efforts aimed advance human health, foster worldwide collaboration, standardize procedural guidelines enhance quality safety practice. In latest project, NMGI develop a unified nomenclature for systemic therapy medicine, diverse terminology currently used. An online survey was distributed member organizations, drawing participation from various geographical locations disciplines. anonymously collected responses physicians, physicists, scientists, radiopharmacists, radiopharmaceutical dosimetrists, technologists, nurse managers, totaling 240 30 countries. Findings revealed prevailing use term targeted therapy, with 52% respondents expressing preference this term. contrast, approximately 37% favored "radiopharmaceutical therapy," whereas 11% "molecular therapy." Other key terms under umbrella also discussed achieve consensus terminology. dynamic fluid should improve communication within field, better reflect technology used, enable comparison results, ultimately lead improved patient outcomes.

Язык: Английский

Процитировано

0

Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer DOI Creative Commons
Habibollah Dadgar, Ali Pashazadeh,

Nasim Norouzbeigi

и другие.

Theranostics, Год журнала: 2025, Номер 15(10), С. 4368 - 4397

Опубликована: Март 18, 2025

Radioligand therapy (RLT) has garnered significant attention due to the recent emergence of innovative and effective theranostic agents, which showed promising therapeutic prognostic results in various cancers. Moreover, understanding interaction between different types radiation biological tissues is essential for optimizing interventions These concepts directly apply clinical RLTs play a crucial role determining efficacy toxicity profile radiopharmaceutical agents. Personalized dosimetry powerful tool that aids estimating patient-specific absorbed doses both tumors normal organs. Dosimetry RLT an area active investigation, as our current relationship dose tissue damage primarily derived from external-beam therapy. Further research necessary comprehensively comprehend this context RLTs. In present review, we thorough examination involvement 177Lu/225Ac radioisotopes induction direct indirect DNA damage, well their influence on initiation repair mechanisms cancer cells neuroendocrine metastatic prostate cancer. Current data indicate high-energy α-emitter can impact structure by causing ionization, leading formation ionized atoms or molecules. This ionization process predominantly leads irreparable intricate double-strand breaks (DSBs). On other hand, majority caused β-emitter indirect, it involves production free radicals subsequent chemical reactions. Beta particles themselves also physically interact with molecule, resulting single-strand (SSBs) potentially reversible DSBs.

Язык: Английский

Процитировано

0

Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET/CT for prostate cancer detection and its comparison with [18F]FDG imaging DOI Creative Commons
Fei Chen,

Hao Zhang,

Y. H. Zhan

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Апрель 25, 2025

Язык: Английский

Процитировано

0